

# CLINICAL TRIAL

XIRIUS

Research



## A Dose Escalation, Phase 1/2 Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)

Rare Eye Disease concerned by the trial :  
X-linked RP

Status of the trial : recruiting  
Orphan drug recognition : No

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion  
opening date : 01/08/2017



Inclusion  
closing date : 31/01/2018

Children



Adults



### Within ERN-EYE members



Principal location of the trial :

**Manchester University Hospitals NHS  
Foundation Trust**

Manchester Royal Eye Hospital  
Oxford Road  
Manchester M13 9WL  
UK

[Contact details](#)



Principal investigator name :


Prof. Paulo Stanga



Other investigators :

None

Funder type : Drug company - Industry



[More informations](#)